
    
      Savolitinib will be administrated 600mg or 400mg once per day (QD). The treatment will be
      discontinued for the patients who experience disease progression, death or experience
      unacceptable toxicity, whichever occurs first. A cycle of study treatment will be defined as
      21 days of continuous dosing.
    
  